

Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.

Catalina Betancur, Maryse Canton, Alain Burgos, Bernard Labeeuw, Danielle Gully, William Rostène, Didier Pélaprat

► **To cite this version:**

Catalina Betancur, Maryse Canton, Alain Burgos, Bernard Labeeuw, Danielle Gully, et al.. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.. European Journal of Pharmacology, Elsevier, 1998, 343 (1), pp.67-77. inserm-00276332

HAL Id: inserm-00276332

<https://www.hal.inserm.fr/inserm-00276332>

Submitted on 29 Apr 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Characterization of binding sites of a new neurotensin receptor antagonist, [³H]SR 142948A, in the rat brain

Catalina Betancur^{a, *}, Maryse Canton^b, Alain Burgos^b, Bernard Labeeuw^b,
Danielle Gully^b, William Rostène^a and Didier Pélaprat^a

^a INSERM U. 339, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine,
75571 Paris Cedex 12, France

^b Sanofi Recherche, 195 route d'Espagne, 31036 Toulouse Cedex, France

*Corresponding author. Tel.: +33-1-49284688; fax: +33-1-43408270; e-mail: betancur@adr.st-antoine.inserm.fr

Abstract

The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of neurotensin receptors, [³H]SR 142948A (2-{{[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino}-adamantane-2-carboxylic acid, hydrochloride), in the rat brain. The binding of [³H]SR 142948A in brain membrane homogenates was specific, time-dependent, reversible and saturable. [³H]SR 142948A bound to an apparently homogeneous population of sites, with a K_d of 3.5 nM and a B_{max} value of 508 fmol/mg of protein, which was 80% higher than that observed in saturation experiments with [³H]neurotensin. [³H]SR 142948A binding was inhibited by SR 142948A, the related nonpeptide receptor antagonist, SR 48692 (2-{{[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl]amino}-adamantane-2-carboxylic acid) and neurotensin. Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine, revealed that [³H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT₁ receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT₂ receptors (80% of the receptors) (K_d =6.8 and 4.8 nM, respectively). The regional distribution of [³H]SR 142948A binding in the rat brain closely matched the distribution of [¹²⁵I]neurotensin binding. In conclusion, these findings indicate that [³H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT₁ and NT₂ receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.

Keywords: [³H]SR 142948A; Neurotensin receptor; Nonpeptide receptor antagonist; Levocabastine; Receptor autoradiography; Brain

1. Introduction

Neurotensin is a 13-amino acid neuropeptide found in the central nervous system and peripheral tissues of numerous mammalian species (Emson *et al.*, 1982; Mai *et al.*, 1987). Neurotensin acts as a neurotransmitter–neuromodulator in a variety of physiological processes. In particular, neurotensin has been shown to play an important role in the modulation of midbrain dopamine transmission (Kasckow and Nemeroff, 1991); neurotensin is also involved in nociception, hypothermia and control of anterior pituitary hormone secretion (Rostène and Alexander, 1997). In the adult rat and mouse brain, neurotensin can bind to two different binding sites which can be distinguished by their affinity for neurotensin (Mazella *et al.*, 1983), as well as by their sensitivity to levocabastine, a histamine H1 receptor antagonist (Schotte *et al.*, 1986). In other species, including humans, rabbits and guinea pigs, only levocabastine-insensitive sites have been detected in the brain (Schotte *et al.*, 1986). Until recently, it was believed that the physiological effects of neurotensin were mediated through a single class of G protein-coupled receptors, corresponding to the levocabastine-insensitive binding sites, cloned from rat brain (Tanaka *et al.*, 1990) and human adenocarcinoma HT-29 cell line (Vita *et al.*, 1993). In contrast, it was assumed that levocabastine-sensitive neurotensin binding sites lacked signalling activity and were thus considered as acceptor sites, devoid of function. Very recently, however, a novel neurotensin receptor (called NT₂) sensitive to levocabastine was cloned in the rat hypothalamus (Chalon *et al.*, 1996) and mouse brain (Mazella *et al.*, 1996). It also belongs to the family of G protein-coupled receptors and has about 40% homology with the previously cloned rat and human neurotensin receptors (NT₁). The biological function of the neurotensin NT₂ receptor remains to be determined.

A major advancement in the field of neurotensin research was provided by the discovery of the first highly potent and selective nonpeptide neurotensin receptor antagonist, SR 48692 (Gully *et al.*, 1993). SR 48692 is orally active, crosses the blood brain barrier and has a long-lasting action; it shows higher affinity for neurotensin NT₁ than for NT₂ receptors. This antagonist can counteract the effects of neurotensin in numerous *in vitro* and *in vivo* assays (Gully *et al.*, 1993); however, SR 48692 is unable to inhibit neurotensin-induced hypothermia and analgesia in rats and mice (Dubuc *et al.*, 1994). This compound also fails to reverse dopamine release in the nucleus accumbens evoked by neurotensin injection in the ventral tegmental area (Steinberg *et al.*, 1994), as well as the hypolocomotion induced by intracerebroventricular administration of the peptide (Pugsley *et al.*, 1995). These findings suggest that these effects of neurotensin could be mediated through a neurotensin receptor subtype which is insensitive to SR 48692 (Le *et al.*, 1996).

Although SR 48692 has proved an important pharmacological tool for studying neurotensin receptors and for exploring the existence of possible neurotensin receptor subtypes, it has certain properties that could limit its usefulness. In particular, SR 48692 has very low aqueous solubility and 100 times lower affinity for the rat brain when compared to the guinea pig brain (Gully *et al.*, 1993). Thus, the tritiated ligand derived from this antagonist, [³H]SR 48692, bound with high affinity to the guinea pig brain ($K_d=2$ nM) (Betancur *et al.*,

1995) and to cells transfected with the rat neurotensin NT₁ receptor ($K_d=3$ nM) (Labbé-Jullié *et al.*, 1995), but exhibited high levels of nonspecific binding when tested in adult rat brain homogenates or sections (unpublished observation).

Recently, Sanofi developed a second nonpeptide antagonist of neurotensin receptors, SR 142948A, which is chemically related to SR 48692 but has better solubility and increased affinity in the rat brain (Gully *et al.*, 1997). SR 142948A recognizes with similar affinity (in the nanomolar range) both neurotensin NT₁ and NT₂ receptors (Gully *et al.*, 1997). Interestingly, in contrast to SR 48692, SR 142948A blocked the hypothermia and analgesia induced by central injection of neurotensin, revealing a wider spectrum of action, probably through inhibition of different neurotensin receptor subtypes (Gully *et al.*, 1997).

In the present study, we examined the binding properties of a newly developed tritiated form of SR 142948A ($[^3\text{H}]$ SR 142948A) in adult rat brain membrane homogenates. Furthermore, we studied the autoradiographic distribution of $[^3\text{H}]$ SR 142948A binding sites in the rat brain and compared it with that of $[^{125}\text{I}]$ neurotensin binding. $[^3\text{H}]$ SR 142948A binding was studied in the presence or absence of levocabastine, in order to determine its binding properties to neurotensin NT₁ and NT₂ receptors.

2. Materials and methods

2.1. Chemicals

SR 142948A (2- $\{[5-(2,6\text{-dimethoxyphenyl})-1-(4-(\text{N}-(3\text{-dimethylaminopropyl})\text{-N-methylcarbamoyl})-2\text{-isopropylphenyl})-1\text{H-pyrazole-3-carbonyl}]$ -amino $\}$ -adamantane-2-carboxylic acid, hydrochloride) (Fig. 1) and SR 48692 (2- $\{[1-(7\text{-chloroquinolin-4-yl})-5-(2,6\text{-dimethoxyphenyl})-1\text{H-pyrazole-3-carbonyl}]$ amino $\}$ -adamantane-2-carboxylic acid) were synthesized at Sanofi Recherche (Montpellier, France). Both compounds were dissolved in dimethylsulfoxide and stored in aliquots at -20°C until the day of the experiment. $[^3\text{H}]$ SR 142948A (83 Ci/mmol) was tritiated at Sanofi Recherche (Alnwick, Great Britain). $[^3\text{H}]$ Neurotensin (104 Ci/mmol) was purchased from New England Nuclear (Les Ulis, France) and monoiodo- $[^{125}\text{I-Tyr}^3]$ neurotensin (2000 Ci/mmol) was iodinated and purified as described previously (Sadoul *et al.*, 1984). Unlabeled neurotensin was purchased from Neosystem Laboratories (Strasbourg, France). Levocabastine was kindly provided by Janssen Pharmaceutica (Beerse, Belgium) and was solubilized in ethanol.

2.2. Preparation of brain membrane homogenates

Male Sprague–Dawley rats (180–220 g, Charles River, Saint Aubain-les-Elboeuf, France) were killed by cervical dislocation. The whole brain (minus the cerebellum) was removed rapidly and homogenized in 10 volumes (original wet weight/volume) of 50 mM Tris–HCl ice-cold buffer (pH 7.4) for 30 s by using a polytron (setting 5). After 20 min of centrifugation at $50\,000\times g$, the pellet was washed and again centrifuged as above. The final pellet was resuspended in binding assay buffer containing 50 mM Tris–HCl (pH 7.4), 1 mM EDTA,

0.1% bovine serum albumin, 1 mM 1,10 orthophenanthroline (Sigma, Saint Louis, MO), 5 mM dithiothreitol and 40 mg/l bacitracin and stored as aliquots in liquid nitrogen until used.

2.3. Binding assays in brain homogenates

Aliquots of brain membranes (300 µg/assay) were incubated in 0.5 ml (final volume) of binding assay buffer containing the appropriate concentrations of [³H]SR 142948A and unlabeled drugs. After incubation at 20°C for 60 min, the assay medium was diluted with 4 ml of ice-cold 50 mM Tris–HCl buffer (pH 7.4) and filtered rapidly under reduced pressure through Whatman glass-fiber GF/B filters pretreated with 0.1% polyethylenimine. The filters were washed 3 times under the same conditions and transferred to vials containing 4 ml of scintillation cocktail. The bound radioactivity was determined by liquid scintillation counting. Nonspecific binding was determined in the presence of 1 µM unlabeled SR 142948A.

Saturation experiments were carried out with increasing concentrations of [³H]SR 142948A (0.05 to 16 nM). In association kinetic experiments, rat brain homogenates were incubated with [³H]SR 142948A (2 nM) for various time periods. For dissociation studies, [³H]SR 142948A was incubated for 30 min with brain membranes, unlabeled SR 142948A was then added at a final concentration of 1 µM and incubations were stopped at the indicated times. Competition studies were conducted with a single concentration of [³H]SR 142948A (2 nM) and at least 10 concentrations of unlabeled ligands. In addition, saturation and competition studies with [³H]SR 142948A were performed in the presence of a constant concentration of levocabastine (10 µM), which selectively inhibits binding to neurotensin NT₂ receptors. The effect of guanyl nucleotides on [³H]SR 142948A binding was examined by adding increasing concentrations of the nonhydrolyzable GTP analog 5'-guanylylimidodiphosphate (Gpp(NH)p) to the binding assay. [³H]neurotensin binding to rat brain membranes was performed as described previously (Goedert *et al.*, 1984), in the presence or absence of levocabastine (10 µM). Nonspecific binding was determined by incubation with 1 µM neurotensin. All experiments were performed 2 or 3 times in triplicate. Data from association, saturation and competition studies were analyzed by using a nonlinear regression program, LIGAND (Munson and Rodbard, 1980). K_i values were calculated according to the Cheng and Prusoff (1973) equation.

2.4. Autoradiography of [³H]SR 142948A binding sites

Adult male rats were killed by decapitation, the brain was removed rapidly, frozen on dry ice and stored at -80°C. Coronal sections (20 µm thick) were cut on a cryostat at -16°C, mounted on slides (Superfrost plus, Menzel-Glaser, Madison, WI) and stored at -20°C until used. [³H]SR 142948A binding was performed by incubating the sections for 60 min at room temperature with 300 µl of 2 nM [³H]SR 142948A in 50 mM Tris–HCl buffer (pH 7.4), containing 1 mM EDTA, 0.1% bovine serum albumin, 40 mg/ml bacitracin and 0.5 mM 1,10 orthophenanthroline, in the presence or absence of 1 µM levocabastine. Additional sections were incubated with 10 µM SR 142948A for the determination of nonspecific binding. After

incubation, the sections were washed 3 times for 10 min each at 4°C in 50 mM Tris–HCl buffer (pH 7.4), containing 1 mM EDTA and 0.1% bovine serum albumin. Slides were then dipped briefly in distilled water and dried under a stream of air. Sections were placed in X-ray cassettes, apposed to Hyperfilm-³H (Amersham, France) for 3 weeks and developed by standard photographic procedures.

2.5. Autoradiography of [¹²⁵I]neurotensin binding sites

[¹²⁵I]Neurotensin binding was performed as described previously (Moyse *et al.*, 1987). Briefly, slide-mounted brain sections were incubated for 60 min at 4°C with 300 µl of 0.3 nM [¹²⁵I]neurotensin in 50 mM Tris–HCl buffer (pH 7.4), containing 5 mM MgCl₂, 0.2% bovine serum albumin and 0.5 mM 1,10 orthophenanthroline, in the presence or absence of 1 µM levocabastine. Nonspecific binding was determined in the presence of 10 µM unlabeled neurotensin. The sections were washed 4 times for 2 min each at 4°C in 40 mM Tris–HCl buffer (pH 7.4), dipped briefly in distilled water and dried. Radiolabeled sections were exposed to Hyperfilm-βmax (Amersham) for 1 week.

2.6. Densitometric analysis

Quantitative optical density measurements of film autoradiographs were carried out with a computer-based image analysis system (HISTO-RAG, Biocom, Les Ulis, France). Optical densities of nonspecific binding were subtracted from total binding to obtain specific binding. Measurements were performed bilaterally on 4 brain sections per level. Values were expressed as nCi/mg tissue by using autoradiographic ³H and ¹²⁵I micro-scales (Amersham) that were exposed together with the tissue sections. Brain structures were identified according to the atlas of Paxinos and Watson (1986).

3. Results

3.1. Biochemical profile of [³H]SR 142948A binding to rat brain membrane homogenates

3.1.1. Tissue concentration linearity

Fig. 2 shows the total, nonspecific and specific binding of [³H]SR 142948A to rat brain homogenates as a function of membrane protein concentration. The specific binding of [³H]SR 142948A measured at 2 nM was linear with increasing protein concentration until 400 µg of protein/tube.

3.1.2. Saturation studies

Fig. 3 shows a saturation isotherm of the binding of [³H]SR 142948A to rat brain membranes. Analysis of the saturation curves by computer-assisted nonlinear regression or by Scatchard analysis (Fig. 3, inset) revealed a single class of high-affinity binding sites ($K_d=3.48\pm 0.22$ nM;

mean±S.E.M., n=3) for radioligand concentrations ranging from 0.05 to 16 nM, with a maximal binding capacity (B_{\max}) of 508.4±45.0 fmol/mg of protein.

3.1.3. Kinetic studies

The specific binding of [3 H]SR 142948A to rat brain membranes was time dependent, reaching a steady state in about 60–80 min at 20°C (Fig. 4A). Fig. 4B illustrates the rate of dissociation, measured at various time intervals after addition of 1 μ M unlabeled SR 142948A at equilibrium binding. The dissociation kinetics revealed a first-order process with a dissociation rate constant (k_{-1}) of 0.021 min $^{-1}$ (mean, n=2). The observed association rate constant (k_{obs}) was 0.033 min $^{-1}$ and the kinetic association constant (k_1), calculated from the equation $k_1=(k_{\text{obs}}-k_{-1})/([^3\text{H}]\text{SR } 142948\text{A})$, was 0.006×10 9 M $^{-1}$ min $^{-1}$. The dissociation constant (K_d) calculated from the ratio k_{-1}/k_1 was 3.5 nM, similar to the dissociation constant determined in saturation studies.

3.1.4. Competition studies

Fig. 5 shows the inhibition of [3 H]SR 142948A binding by increasing concentrations of unlabeled SR 142948A, SR 48692 and neurotensin in rat brain homogenates. The K_i value obtained for unlabeled SR 142948A, 5.0±0.4 nM, was close to the values determined in kinetic studies (Hill coefficient, $n_H=0.98\pm0.01$). The binding of [3 H]SR 142948A to rat brain membranes was fully displaced by the natural ligand neurotensin, as well as by the previously described neurotensin receptor antagonist SR 48692, a nonpeptide molecule chemically related to SR 142948A. These competition curves gave K_i values of 32.8±5.9 nM ($n_H=0.99\pm0.10$) for neurotensin and 123.6±15.7 nM ($n_H=0.95\pm0.06$) for SR 48692.

3.1.5. Effect of levocabastine on [3 H]SR 142948A and [3 H]neurotensin binding

The addition of increasing concentrations of levocabastine to the [3 H]SR 142948A binding assay resulted in progressive blockade of neurotensin NT $_2$ receptors (Fig. 6). Concentrations greater than 1 μ M levocabastine completely inhibited the binding of [3 H]SR 142948A to NT $_2$ receptors, which constituted 80% of the whole population of sites. The presence of 10 μ M levocabastine in the [3 H]SR 142948A binding assay revealed neurotensin NT $_1$ receptors, which were recognized by SR 142948A with an IC $_{50}$ value of 4.0±0.3 nM, in the same nanomolar range as for experiments without levocabastine (IC $_{50}=7.0\pm1.5$ nM).

Saturation experiments were also performed in the presence or absence of 10 μ M levocabastine with a fixed concentration of [3 H]SR 142948A and increasing concentrations of unlabeled SR 142948A. Scatchard analysis of [3 H]SR 142948A binding data in the absence of levocabastine yielded a linear plot (Fig. 7A), indicating the presence of a homogeneous population of binding sites ($K_d=6.1\pm1.6$ nM, $B_{\max}=527\pm22$ fmol/mg protein; n=3). However, the parallel leftward shift of this straight line obtained in the presence of 10 μ M levocabastine indicated binding to neurotensin NT $_1$ receptors ($K_d=3.4\pm0.5$ nM, $B_{\max}=104\pm8$ fmol/mg protein) and, by difference, revealed neurotensin NT $_2$ receptors ($K_d=8.5\pm4.1$ nM,

B_{\max} =422±58 fmol/mg protein). These data confirmed that [³H]SR 142948A exhibits similar affinities for the two subtypes of neurotensin receptors. Similar experiments performed with [³H]neurotensin (Fig. 7B) revealed K_d values comparable to those of [³H] SR 142948A (6.8 and 4.8 nM for NT₁ and NT₂ receptors, respectively). However, [³H]neurotensin bound to a lower number of binding sites than [³H]SR 142948A (B_{\max} values of 32 and 265 fmol/mg for NT₁ and NT₂ receptors, respectively).

3.1.6. Effect of guanyl nucleotides on [³H]SR 142948A binding

In order to determine whether the binding of [³H]SR 142948A was sensitive to guanyl nucleotides, we examined the affinity of the radioligand in the presence of Gpp(NH)p, a nonhydrolyzable analog of GTP. The addition of Gpp(NH)p in concentrations up to 100 μM did not modify the specific binding of [³H]SR 142948A to rat brain membranes (data not shown).

3.2. Autoradiographic localization of [³H]SR 142948A binding sites in the rat brain: Comparison with [¹²⁵I]neurotensin binding

Preliminary experiments showed that the characteristics of [³H]SR 142948A binding to rat midbrain sections were similar to those observed for brain membrane homogenates. [³H]SR 142948A binding was saturable and reached a steady state by 60 min. Specific [³H]SR 142948A binding was approximately 90% of the total binding, as determined with 2 nM radioligand. Analysis of competition studies performed on rat midbrain sections showed that SR 142948A, SR 48692 and neurotensin induced a dose-dependent and complete inhibition of [³H]SR 142948A binding (data not shown).

Fig. 8 shows the regional distribution of [³H]SR 142948A and [¹²⁵I]neurotensin binding sites in the rat brain. The highest density of [³H]SR 142948A and [¹²⁵I]neurotensin binding was present in the midbrain, in the ventral tegmental area and substantia nigra pars compacta. Intense labeling was also observed in the perirhinal area as well as in the dorsal peduncular, anterior cingulate and agranular insular cortices, posteromedial cortical amygdaloid nucleus, medial habenula and ventral dentate gyrus. The endopiriform nucleus, septohippocampal nucleus, central amygdaloid nucleus and zona incerta exhibited moderate levels of binding. Finally, a low density of binding sites was observed in the frontal, parietal, temporal and retrosplenial granular cortices, caudate putamen, nucleus accumbens, lateral septum, hypothalamus, hippocampus, substantia nigra pars reticulata and in the superficial gray layer of the superior colliculus.

Table 1 shows the comparative distribution of [³H]SR 142948A and [¹²⁵I]neurotensin binding sites in the rat brain, in the presence or absence of levocabastine. An excellent correlation between the regional distribution of the two ligands was observed, in agreement with the autoradiographic localization of neurotensin receptors in rat brain described previously (Moyses *et al.*, 1987). The presence of levocabastine in the incubation buffer inhibited binding to neurotensin NT₂ receptors and decreased the amount of labeling with

[³H]SR 142948A and [¹²⁵I]neurotensin in all brain regions studied, indicating that both ligands labeled neurotensin NT₁ and NT₂ receptors. This result is in agreement with the ubiquitous distribution of NT₂ receptors in the rat brain (Schotte *et al.*, 1986).

4. Discussion

The binding of the nonpeptide neurotensin receptor antagonist [³H]SR 142948A to rat brain membranes was rapid, tissue concentration and time dependent, saturable and reversible. Scatchard analyses of saturation experiments indicated that [³H]SR 142948A binds with high affinity ($K_d=3.5$ nM) and apparently recognizes a single class of binding sites. The number of sites labeled by [³H]SR 142948A ($B_{max}=508$ fmol/mg protein) was 80% greater than the B_{max} value determined with [³H]neurotensin under the same experimental conditions (297 fmol/mg protein). Competition experiments with unlabeled SR 142948A yielded a Hill coefficient near unity, further suggesting that the antagonist bound to an apparently homogeneous population of binding sites.

The potencies of the neurotensin receptor antagonists SR 142948A and SR 48692 in inhibiting specific [³H]SR 142948A binding ($K_i=5$ and 123.6 nM, respectively) were similar to their previously reported potencies in displacing [¹²⁵I]neurotensin binding in adult rat brain homogenates ($IC_{50}=3.96$ and 82 nM for SR 142948A and SR 48692, respectively) (Gully *et al.*, 1997). In contrast, the potency of the natural peptide agonist neurotensin for inhibiting [³H]SR 142948A binding ($K_i=32.8$ nM) was 10-fold lower than its potency in displacing [¹²⁵I]neurotensin binding ($IC_{50}=3.2$ nM). This is consistent with results obtained with other receptor systems, demonstrating that estimates of agonist affinity are lower when an antagonist rather than an agonist radioligand is displaced. Indeed, a reduced potency for agonists to compete against radiolabeled antagonist ligands has been observed previously for neurotensin receptors in the guinea pig brain (Betancur *et al.*, 1995), as well as for muscarinic cholinergic receptors (Waelbroeck *et al.*, 1982), cholecystokinin CCKA (Chang *et al.*, 1986; Talkad *et al.*, 1994) and CCKB receptors (Chang *et al.*, 1989), tachykinin NK₁ receptors (McLean *et al.*, 1991) and 5-HT₂ receptors (Teitler *et al.*, 1990). These findings have been interpreted as indicating the existence of different conformational states of the same receptor, with different affinities for agonist and antagonist ligands (Schwartz *et al.*, 1995).

The higher number of receptors detected with [³H]SR 142948A when compared with the number detected with the agonist radioligand, [³H]neurotensin, also supports this hypothesis. The ability of radiolabeled nonpeptide antagonists to recognize a larger number of receptors, characterized by low affinity for the agonist, than agonist-derived radioligands appears to be a common phenomenon. For instance, we showed previously that in the guinea pig brain the number of binding sites labeled by the antagonist [³H]SR 48692 exceeded by 20-fold the number of receptors labeled with the agonist [¹²⁵I]neurotensin (Betancur *et al.*, 1995). The binding sites detected by [³H]SR 48692 were characterized by a low affinity for neurotensin and were insensitive to GTP, suggesting that they represent the uncoupled form of the neurotensin receptor. These data, together with current hypotheses on the molecular

interactions of ligands with their receptors, suggest that agonists bind with high affinity to the active receptor conformation, whereas antagonists bind with higher affinity to the inactive conformation (Schwartz *et al.*, 1995). Thus, peptide agonists and nonpeptide antagonists act as allosteric competitive ligands by binding in a mutually exclusive fashion to sites occurring in different receptor conformations. In support of this model, recent site-directed mutational studies of the rat neurotensin NT₁ receptor showed that mutations in the N-terminal part eliminate neurotensin binding without affecting the binding of [³H]SR 48692 (Labbé-Jullié *et al.*, 1995). This finding suggests the existence of distinct agonist and antagonist binding domains on the neurotensin NT₁ receptor, similarly to what has been reported for several other neuropeptide receptors (for review, see Betancur *et al.*, 1997).

Levocabastine is a nonpeptide antagonist of histamine H1 receptors that is structurally unrelated to neurotensin (Stockbroekx *et al.*, 1986), but binds also to neurotensin NT₂ receptors (Schotte *et al.*, 1986). The recent cloning of the mouse NT₂ receptor and its expression in *Xenopus* oocytes indicated that levocabastine acts as an agonist in this system, since it triggers a Cl⁻ inward current, as does neurotensin (Mazella *et al.*, 1996). Saturation and competition experiments performed with or without levocabastine indicated that [³H]SR 142948A bound with high affinity to neurotensin NT₁ and NT₂ receptors (K_d=3.4 and 8.5 nM, respectively). Indeed, the addition of levocabastine to the [³H]SR 142948A binding assay caused a parallel leftward shift of the Scatchard plot, indicating the displacement of [³H]SR 142948A binding from levocabastine-sensitive NT₂ receptors. The similar affinity of [³H]SR 142948A for both subtypes of neurotensin receptors explains the apparently homogeneous population of binding sites detected with this ligand in the absence of levocabastine. Moreover, our results indicate that neurotensin NT₂ receptors constitute 80% of the whole population of sites labeled by [³H]SR 142948A (B_{max}=104 and 422 fmol/mg protein for NT₁ and NT₂ receptors, respectively) on rat brain membranes.

Guanyl nucleotides differentially affect agonist and antagonist binding in several neurotransmitter receptor systems. Accordingly, guanyl nucleotides have been reported to significantly reduce [¹²⁵I]neurotensin binding to NT₁ receptors, by interfering with the formation of the high-affinity agonist-receptor-G protein ternary complex (Hermans *et al.*, 1996). In contrast, the present study showed that addition of Gpp(NH)p had no effect on specific [³H]SR 142948A binding. This finding is consistent with previous data showing that antagonist ligands bind with high affinity to the G protein-uncoupled state of receptors (Teitler *et al.*, 1990; Rosenkilde *et al.*, 1994; Betancur *et al.*, 1995). It should be noted, however, that the levocabastine-sensitive neurotensin binding site is insensitive to GTP (Vincent, 1995), although recent data indicate that the cloned mouse neurotensin NT₂ receptor is coupled functionally to phospholipase C when expressed in oocytes (Mazella *et al.*, 1996). Other studies have shown that an absence of GTP-sensitive binding does not necessarily indicate failure to activate a second messenger cascade (Chung *et al.*, 1988; Maeda *et al.*, 1990; Hermans *et al.*, 1996).

The different sensitivity to Gpp(NH)p of neurotensin NT₁ and NT₂ receptors is particularly interesting in view of the fact that the lowest homology between the two

neurotensin receptors is in their third cytoplasmic loop and C-terminal domain (Chalon *et al.*, 1996; Mazella *et al.*, 1996), two regions implicated in the coupling to G proteins (Yamada *et al.*, 1994; Hermans *et al.*, 1996). Furthermore, it has been proposed that the extremely high number of Ser/Thr residues in the third intracytoplasmic loop and the C-terminal domain of the neurotensin NT₂ receptor protein could be associated with a basal phosphorylated state resulting in desensitization of the receptor (Mazella *et al.*, 1996). This could result in a higher proportion of receptors in the uncoupled form expressed in the membrane and might explain the insensitivity of the NT₂ receptor to GTP analogs. The use of recently developed radiolabeled agonist ligands specific for the G protein-coupled state of neurotensin receptors (Gaudriault *et al.*, 1996), in the presence or absence of levocabastine, could help to determine the different states of coupling of neurotensin NT₁ and NT₂ receptors.

The autoradiographic distribution of [³H]SR 142948A binding in sections of rat brain was consistent with its selective binding to neurotensin receptors. The heterogeneous pattern of specific [³H]SR 142948A binding closely matched the localization of [¹²⁵I]neurotensin binding observed in adjacent sections. The addition of levocabastine to the incubation buffer resulted in a small and diffuse reduction of [³H]SR 142948A and [¹²⁵I]neurotensin binding in all brain structures studied, in agreement with previous studies indicating that neurotensin NT₂ receptors are distributed throughout the rat central nervous system (Schotte *et al.*, 1986; Kitabgi *et al.*, 1987) and are predominantly associated with glial cells (Schotte *et al.*, 1988). The ubiquitous distribution of neurotensin NT₂ receptors contrasts with the highly regional localization of NT₁ receptors in the brain. Indeed, NT₁ receptors are particularly abundant in brain regions rich in dopamine neurons, such as the substantia nigra and the ventral tegmental area, as well as in certain cortical areas. These results are in agreement with the previously described distribution of [¹²⁵I]neurotensin binding (Moyses *et al.*, 1987) and neurotensin NT₁ receptor mRNA (Nicot *et al.*, 1994) observed in the rat brain.

The functional characterization of the actions of SR 142948A in the central nervous system showed that this compound, like the first-generation neurotensin receptor antagonist SR 48692, antagonizes the turning behavior induced by intrastriatal injection of neurotensin in mice as well as acetylcholine release evoked by neurotensin in the striatum (Gully *et al.*, 1993 and Gully *et al.*, 1997). Neither compound modified dopamine release in the nucleus accumbens after injection of neurotensin into the ventral tegmental area (Steinberg *et al.*, 1994; Gully *et al.*, 1997). However, unlike SR 48692, SR 142948A blocked the hypothermia and analgesia induced by central injection of neurotensin in rodents (Gully *et al.*, 1997). These results suggest that SR 142948A may interact with a neurotensin receptor subtype which is not blocked by SR 48692. It would be interesting to assess the potential involvement of the recently identified neurotensin NT₂ receptor in the mediation of the hypothermia and anti-nociceptive effects induced by neurotensin.

In conclusion, [³H]SR 142948A represents a new potent nonpeptide antagonist radioligand specific for neurotensin receptors. The compound binds to rat neurotensin NT₁ and NT₂ receptors with nanomolar affinity, close to that of the natural ligand neurotensin. The ligand previously described, [³H]SR 48692, exhibits a higher affinity for NT₁ than for NT₂

receptors and has a low ratio of total binding to nonspecific binding in rat brain membranes and tissue sections, which limits its utility. Consequently, the availability of [³H]SR 142948A provides a valuable tool for the study of neurotensin receptors in the central nervous system.

Acknowledgements

We thank A.M. Lhiaubet for labeling [¹²⁵I]neurotensin. C.B. is supported by a post-doctoral fellowship from INSERM (Institut National de la Santé et de la Recherche Médicale), France.

References

- Betancur, C., Canton, M., Gully, D., Vela, G., Pélaprat, D. and Rostène, W. 1995. Characterization and distribution of binding sites for a new neurotensin receptor antagonist ligand, [³H]SR 48692, in the guinea pig brain. *J. Pharmacol. Exp. Ther.* 273, pp. 1450–1458
- Betancur, C., Azzi, M. and Rostène, W. 1997. Nonpeptide antagonists of neuropeptide receptors: Tools for research and therapy. *Trends Pharmacol. Sci.* 18, pp. 372–386
- Chalon, P., Vita, N., Kaghad, M., Guillemot, M., Bonnin, J., Delpech, B., Le Fur, G., Ferrara, P. and Caput, D. 1996. Molecular cloning of a levocabastine-sensitive neurotensin binding site. *FEBS Lett.* 386, pp. 91–94
- Chang, R.S.L., Lotti, V.J., Chen, T.B. and Kunkel, K.A. 1986. Characterization of the binding of [³H]-(\pm)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. *Mol. Pharmacol.* 30, pp. 212–217
- Chang, R.S.L., Chen, T.B., Bock, M.G., Freidinger, R.M., Chen, R., Rosegay, A. and Lotti, V.J. 1989. Characterization of the binding of [³H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. *Mol. Pharmacol.* 35, pp. 803–808
- Cheng, Y. and Prusoff, W. 1973. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50% inhibition (IC_{50}) of an enzymatic reaction. *Biochem. Pharmacol.* 22, pp. 3099–3108
- Chung, F.Z., Wang, C.D., Potter, P.C., Venter, J.C. and Fraser, C.M. 1988. Site-directed mutagenesis and continuous expression of human β -adrenergic receptors. *J. Biol. Chem.* 263, pp. 4052–4055
- Dubuc, I., Costentin, J., Terranova, J.P., Barnouin, M.C., Soubrié, P., Le Fur, G., Rostène, W. and Kitabgi, P. 1994. The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes. *Br. J. Pharmacol.* 112, pp. 352–354
- Emson, P.C., Goedert, M., Horsfield, P.M., Rioux, F. and St. Pierre, S. 1982. The regional distribution and chromatographic characterization of neurotensin-like immunoreactivity in the rat central nervous system. *J. Neurochem.* 38, pp. 992–999
- Gaudriault, G., Zsürger, N. and Vincent, J.P. 1996. Radiolabeled ligands specific for the G protein-coupled state of neurotensin receptors. *J. Neurochem.* 67, pp. 2590–2598
- Goedert, M., Pittaway, K., Williams, B.J. and Emson, P.C. 1984. Specific binding of tritiated neurotensin to rat brain membranes: Characterization and regional distribution. *Brain Res.* 304, pp. 71–81
- Gully, D., Canton, M., Boigegrain, R., Jeanjean, F., Molimard, J.C., Poncelet, M., Guedet, C., Heaulme, M., Leyris, R., Brouard, A., Pélaprat, D., Labbé-Jullié, C., Mazella, J., Soubrié, P., Maffrand, J.P., Rostène, W., Kitabgi, P. and Le Fur, G. 1993. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of neurotensin receptor. *Proc. Natl. Acad. Sci. USA* 90, pp. 65–69

- Gully, D., Labeeuw, B., Boigegrain, R., Oury-Donat, F., Bachy, A., Poncelet, M., Steinberg, R., Suaud-Chagny, M.F., Santucci, V., Vita, N., Pecceu, F., Labbé-Jullié, C., Kitabgi, P., Soubrié, P., Le Fur, G. and Maffrand, J.P. 1997. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. *J. Pharmacol. Exp. Ther.* 280, pp. 802–812
- Hermans, E., Octave, J.N. and Maloteaux, J.M. 1996. Interaction of the COOH-terminal domain of the neurotensin receptor with a G protein does not control the phospholipase C activation but is involved in the agonist-induced internalization. *Mol. Pharmacol.* 49, pp. 365–372
- Kasckow, J. and Nemeroff, C.B. 1991. The neurobiology of neurotensin: Focus on neurotensin–dopamine interactions. *Regul. Pept.* 36, pp. 153–164
- Kitabgi, P., Rostène, W., Dussaillant, M., Schotte, A., Laduron, P.M. and Vincent, J.P. 1987. Two populations of neurotensin binding sites in murine brain: Discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. *Eur. J. Pharmacol.* 140, pp. 285–293
- Labbé-Jullié, C., Botto, J.M., Mas, M.V., Chabry, J., Mazella, J., Vincent, J.P., Gully, D., Maffrand, J.P. and Kitabgi, P. 1995. [³H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: Characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. *Mol. Pharmacol.* 47, pp. 1050–1056
- Le, F., Cusak, B. and Richelson, E. 1996. The neurotensin receptor: Is there more than one subtype?. *Trends Pharmacol. Sci.* 17, pp. 1–3
- Maeda, S., Lameh, J., Mallet, W.G., Philip, M., Ramachandran, J. and Sadée, W. 1990. Internalization of the Hm1 muscarinic cholinergic receptor involves the third cytoplasmic loop. *FEBS Lett.* 269, pp. 386–388
- Mai, J., Triepel, K.J. and Metz, J. 1987. Neurotensin in the human brain. *Neuroscience* 22, pp. 499–524
- Mazella, J., Poustis, C., Labbé, C., Checler, F., Kitabgi, P., Granier, C., Van Rietschoten, J. and Vincent, J.P. 1983. Monoiodo Trp11-neurotensin, a highly radioactive ligand of neurotensin receptors: Preparation, biological activity, and binding properties to rat brain synaptic membranes. *J. Biol. Chem.* 258, pp. 3476–3481
- Mazella, J., Botto, J.M., Guillemare, E., Coppola, T., Sarret, P. and Vincent, J.P. 1996. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. *J. Neurosci.* 16, pp. 5613–5620
- McLean, S., Ganong, A.H., Seeger, T.F., Bryce, D.K., Pratt, K.G., Reynolds, L.S., Siok, C.J., Lowe III, J.A. and Heym, J. 1991. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. *Science* 251, pp. 437–439
- Moyse, E., Rostène, W., Vial, M., Leonard, K., Mazella, J., Kitabgi, P., Vincent, J.P. and Beaudet, A. 1987. Distribution of neurotensin binding sites in rat brain: A light microscopic radioautographic study using monoiodo [¹²⁵I]Tyr3-neurotensin. *Neuroscience* 22, pp. 525–536
- Munson, P.J. and Rodbard, D. 1980. LIGAND: A versatile computerized approach for characterization of ligand-binding systems. *Anal. Biochem.* 107, pp. 220–239
- Nicot, A., Rostène, W. and Béro, A. 1994. Neurotensin receptor expression in the rat forebrain and midbrain: A combined analysis by *in situ* hybridization and receptor autoradiography. *J. Comp. Neurol.* 341, pp. 407–419
- Paxinos, G., Watson, C. 1986. *The Rat Brain in Stereotaxic Coordinates*, 2nd ed. Academic Press, Sydney.
- Pugsley, T.A., Akunne, H.C., Whetzel, S.Z., Demattos, S., Corbin, A.E., Wiley, J.N., Wustrow, D.J., Wise, L.D. and Heffner, T.G. 1995. Differential effects of the nonpeptide neurotensin

- antagonist, SR 48692, on the pharmacological effects of neurotensin agonists. *Peptides* 16, pp. 37–44
- Rosenkilde, M.M., Cahir, M., Gether, U., Hjorth, S.A. and Schwartz, T.W. 1994. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. *J. Biol. Chem.* 269, pp. 28160–28164
- Rostène, W.H. and Alexander, M.J. 1997. Neurotensin and neuroendocrine regulation. *Front. Neuroendocrinol.* 18, p. 115
- Sadoul, J.L., Mazella, J., Amar, S., Kitabgi, P. and Vincent, J.P. 1984. Preparation of neurotensin selectively iodinated on the tyrosine 3 residue. Biological activity and binding properties on mammalian neurotensin receptors. *Biochem. Biophys. Res. Commun.* 120, pp. 812–819
- Schotte, A., Leysen, J.E. and Laduron, P.M. 1986. Evidence for a displaceable non-specific [³H]neurotensin binding site in rat brain. *Naunyn Schmiedebergs Arch. Pharmacol.* 333, pp. 400–405
- Schotte, A., Rostène, W. and Laduron, P.M. 1988. Different subcellular localization of neurotensin receptor and neurotensin acceptor sites in the rat brain dopaminergic system. *J. Neurochem.* 50, pp. 1026–1031
- Schwartz, T.W., Gether, U., Schambye, H.T. and Hjorth, S.A. 1995. Molecular mechanism of action of nonpeptide ligands for peptide receptors. *Curr. Pharm. Design* 1, pp. 355–372
- Steinberg, R., Brun, P., Fournier, M., Souilhac, J., Rodier, D., Mons, G., Terranova, J.P., Le Fur, G. and Soubrié, P. 1994. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. *Neuroscience* 59, pp. 921–929
- Stockbroekx, R.A., Luyckx, M.G., Willems, J.M., Janssen, M.A.C., Bracke, J.O.M.M., Joosen, B.L.P. and Van Wauwe, J.P. 1986. Levocabastine (R 50 547), the prototype of a chemical series of compounds with specific H1-antihistamine activity. *Drug Dev. Res.* 8, pp. 87–93
- Talkad, V.D., Fortune, K.P., Pollo, D.A., Shah, G.N., Wank, S.A. and Gardner, J.D. 1994. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. *Proc. Natl. Acad. Sci. USA* 91, pp. 1868–1872
- Tanaka, K., Masu, M. and Nakanishi, S. 1990. Structure and functional expression of the cloned rat neurotensin receptor. *Neuron* 4, pp. 847–854
- Teitler, M., Leonhardt, S., Weisberg, E.L. and Hoffman, B.J. 1990. 4-[¹²⁵I]iodo-(2,5-dimethoxy)phenylisopropylamine and [³H]ketanserin labeling of 5-hydroxytryptamine₂ (5HT₂) receptors in mammalian cells transfected with a rat 5HT₂ cDNA: Evidence for multiple states and not multiple 5HT₂ receptor subtypes. *Mol. Pharmacol.* 38, pp. 594–598
- Vincent, J.P. 1995. Neurotensin receptors: Binding properties, transduction pathways and structure. *Cell. Mol. Neurobiol.* 15, pp. 501–512
- Vita, N., Laurent, P., Leport, S., Chalon, P., Dumont, X., Kaghad, M., Gully, D., Le Fur, G., Ferrara, P. and Caput, D. 1993. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. *FEBS Lett.* 317, pp. 139–142
- Waelbroeck, M., Robberecht, P., Chatelain, P. and Christophe, J. 1982. Rat cardiac muscarinic receptors. I. Effects of guanine nucleotides on high- and low-affinity binding sites. *Mol. Pharmacol.* 21, pp. 581–588
- Yamada, M., Yamada, M., Watson, M.A. and Richelson, E. 1994. Deletion of the putative third intracellular loop of the rat neurotensin receptor abolishes phosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells. *Mol. Pharmacol.* 46, pp. 470–476

Table 1. Regional distribution of [³H]SR 142948A and [¹²⁵I]neurotensin binding sites in the rat brain, in the presence or absence of levocabastine

Brain area	Specific Binding			
	[³ H]SR 142948A		[¹²⁵ I]neurotensin	
	– levo	+ levo	– levo	+ levo
Cerebral cortex				
Frontal cortex	1.91 ± 0.11	1.12 ± 0.02	0.39 ± 0.03	0.29 ± 0.01
Anterior cingulate cortex	6.61 ± 0.27	6.41 ± 0.14	2.01 ± 0.16	1.79 ± 0.14
Dorsal peduncular cortex	9.44 ± 0.18	7.67 ± 0.27	2.47 ± 0.39	1.80 ± 0.09
Agranular insular cortex	7.58 ± 0.21	5.66 ± 0.51	1.62 ± 0.19	1.05 ± 0.09
Dorsal endopiriform nucleus	5.06 ± 0.12	4.59 ± 0.09	1.82 ± 0.13	1.15 ± 0.07
Parietal cortex	1.84 ± 0.05	0.82 ± 0.05	0.40 ± 0.02	0.27 ± 0.01
Perirhinal area	10.54 ± 0.29	8.98 ± 0.22	2.51 ± 0.32	2.29 ± 0.05
Retrosplenial granular cortex	3.11 ± 0.09	1.98 ± 0.12	1.07 ± 0.03	0.84 ± 0.06
Temporal cortex	2.22 ± 0.05	1.01 ± 0.06	0.47 ± 0.01	0.33 ± 0.01
Forebrain				
Septohippocampal nucleus	5.90 ± 0.27	5.50 ± 0.29	2.09 ± 0.47	2.01 ± 0.17
Lateral septal nucleus, dorsal part	5.99 ± 0.25	4.65 ± 0.10	1.13 ± 0.02	1.02 ± 0.05
Basal ganglia				
Caudate putamen (striatum)	2.57 ± 0.13	2.12 ± 0.06	0.58 ± 0.02	0.51 ± 0.02
Accumbens nucleus, shell	2.62 ± 0.08	1.66 ± 0.07	0.52 ± 0.02	0.35 ± 0.01
Accumbens nucleus, core	2.39 ± 0.09	1.55 ± 0.06	0.55 ± 0.03	0.37 ± 0.01
Amygdala				
Central amygdaloid nucleus	5.00 ± 0.33	3.10 ± 0.09	1.29 ± 0.09	0.93 ± 0.02
Posteromedial cortical amygdaloid nucleus	9.17 ± 0.38	8.06 ± 0.26	1.83 ± 0.20	1.60 ± 0.12
Diencephalon				
Zona incerta	7.84 ± 0.14	5.67 ± 0.46	1.61 ± 0.06	1.32 ± 0.03
Lateral habenular nucleus	5.41 ± 0.20	4.01 ± 0.11	1.20 ± 0.06	0.80 ± 0.04
Medial habenular nucleus	10.68 ± 0.48	9.01 ± 0.50	2.63 ± 0.14	1.92 ± 0.07
Hippocampal formation				
Dentate gyrus, ventral part	8.41 ± 0.44	7.64 ± 0.31	1.19 ± 0.08	0.98 ± 0.14
Midbrain				
Substantia nigra, pars compacta	14.25 ± 1.08	11.34 ± 1.08	2.38 ± 0.10	2.05 ± 0.26
Substantia nigra, pars reticulata	3.21 ± 0.13	2.79 ± 0.14	0.99 ± 0.05	0.83 ± 0.07
Ventral tegmental area	15.10 ± 1.08	9.77 ± 0.97	2.18 ± 0.17	1.71 ± 0.19
Superficial gray layer of the superior colliculus	4.10 ± 0.13	2.28 ± 0.08	0.82 ± 0.03	0.64 ± 0.03

[³H]SR 142948A and [¹²⁵I]neurotensin specific binding to neurotensin NT₁ and NT₂ receptors was determined on rat brain sections by autoradiography, in the presence (+ levo) or absence (– levo) of levocabastine (1 μM). The occlusion of neurotensin NT₂ receptors by levocabastine allowed detection of NT₁ receptors. The difference between binding in the absence and in the presence of levocabastine represents binding to NT₂ receptors. Optical densities were measured bilaterally on 4 brain sections per level and expressed as mean ± S.E.M. nCi/mg tissue.




Fig. 1. Chemical structure of SR 142948A. *: location of the 3 tritium atoms.




Fig. 2. [^3H]SR 142948A binding as a function of increasing protein concentrations. Various concentrations of rat brain membranes were incubated with 2 nM [^3H]SR 142948A for 60 min at 20°C. Nonspecific binding was determined with 1 μM unlabeled SR 142948A. Specific binding was defined as the difference between total and nonspecific binding. The data represent the mean of triplicate determinations.




Fig. 3. Saturation analysis and Scatchard plot (inset) of [³H]SR 142948A binding to rat brain membranes. Membranes were incubated for 60 min at 20°C over a concentration range of [³H]SR 142948A (0.05 to 16 nM); nonspecific binding was defined with 1 μM unlabeled SR 142948A. The data shown are from one of 3 experiments performed in triplicate.




Fig. 4. Association (A) and dissociation (B) kinetics of specific [³H]SR 142948A binding to rat brain membranes. (A) The association of 2 nM [³H]SR 142948A binding was determined at various time intervals. (B) Time course of dissociation of [³H]SR 142948A binding, initiated with 1 μ M unlabeled SR 142948A. The points shown are means of triplicate determinations from a representative experiment.




Fig. 5. Inhibition of specific $[^3\text{H}]$ SR 142948A binding to rat brain membranes by increasing concentrations of SR 142948A, SR 48692 and neurotensin. Results represent the means \pm S.E.M. of 3 independent experiments performed in triplicate.




Fig. 6. Inhibition of specific [³H]SR 142948A binding to rat brain membranes by SR 142948A, levocabastine and SR 142948A in the presence of a constant concentration of levocabastine (10 μM). Specific binding of [³H]SR 142948A without levocabastine represents 100%. In the absence of levocabastine, SR 142948A (●) inhibited [³H]SR 142948A binding to neurotensin NT₁ and NT₂ receptors. Levocabastine (◆) inhibited binding of [³H]SR 142948A to NT₂ receptors (80% of the receptors). In the presence of 10 μM levocabastine, SR 142948A (□) inhibited [³H]SR 142948A binding to NT₁ receptors (20% of the receptors). The data shown are from a single experiment performed in triplicate. The experiment was repeated 3 times with similar results.




Fig. 7. Scatchard analysis of saturation of [³H]SR 142948A (A) and [³H]neurotensin (B) binding to rat brain membranes performed with or without 10 μ M levocabastine. [³H]SR 142948A and [³H]neurotensin bound to neurotensin NT₁ and NT₂ receptors; the addition of 10 μ M levocabastine to the binding assay blocked levocabastine-sensitive NT₂ receptors and revealed NT₁ receptors. The NT₂ receptor data were calculated as the difference between the results obtained in the absence and in the presence of levocabastine. The values are from typical experiments and represent the means of triplicate determinations.




Fig. 8. Autoradiographic distribution of [^3H]SR 142948A (left) and [^{125}I]neurotensin (right) binding sites in coronal sections of the rat brain. Photographs show [^3H]SR 142948A and [^{125}I]neurotensin binding in the absence of levocabastine. Nonspecific binding was determined in the presence of 10 μM unlabeled SR 142948A or neurotensin, respectively, and was indistinguishable from background. Abbreviations: CPu=caudate putamen; DG=ventral dentate gyrus; En=endopiriform nucleus; Hb=habenula; Hi=hippocampus; LS=lateral septum; Prh=perirhinal area; RSG=retrosplenial granular cortex; SNC=substantia nigra, pars compacta; SNR=substantia nigra, pars reticulata; VTA=ventral tegmental area; ZI=zona incerta.